Literature DB >> 20827516

From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?

Monica Carpenedo1, Enrico Maria Pogliani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20827516     DOI： 10.1007/s11739-010-0454-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  14 in total

1.  Treatment outcome in a cohort of young patients with polycythemia vera.

Authors:  Marco Ruggeri; Silvia Finotto; Stefania Fortuna; Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

2.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

3.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Polycythemia vera.

Authors:  Raffaele Landolfi; Maria Anna Nicolazzi; Angelo Porfidia; Leonardo Di Gennaro
Journal:  Intern Emerg Med       Date:  2010-03-16       Impact factor: 3.397

Review 6.  Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.

Authors:  Andreas Reiter; Christoph Walz; Nicholas C P Cross
Journal:  Curr Drug Targets       Date:  2007-02       Impact factor: 3.465

7.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

8.  Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

Authors:  Francesco Passamonti; Lucia Malabarba; Ester Orlandi; Claudia Baratè; Angelo Canevari; Ercole Brusamolino; Maurizio Bonfichi; Luca Arcaini; Sabrina Caberlon; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  Imatinib effect on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Srdan Verstovsek; Donghoon Yoon; Ko-Tung Chang; Taghi Manshouri; Roberto Nussenzveig; Jorge Cortes; William Vainchenker; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-06       Impact factor: 3.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.